Several medicines are poised to reach new heights after winning key endorsements from European drug regulators. | Among those ...

Daiichi Sankyo Company, Ltd (TSE: 4568) has appointed Hiroyuki Okuzawa, 62, to succeed Sunao Manabe, DVM, Ph.D. as Chief ...

This is just the latest step Daiichi Sankyo has taken to achieve its five-year goals. In January of this year, the company announced a new smart research facility in San Diego. 2 The goal of this ...

TOKYO, January 31, 2025--(BUSINESS WIRE)--Daiichi Sankyo Company, Ltd (TSE: 4568) has appointed Hiroyuki Okuzawa, 62, to succeed Sunao Manabe, DVM, Ph.D. as Chief Executive Officer (CEO ...

Disclaimer: This article has been developed and funded by Daiichi Sankyo. Daiichi Sankyo has more ... but with the agility and psychology of a start-up company. Success hinges on the right people ...

Daiichi Sankyo Company, Ltd (TSE: 4568) has appointed Hiroyuki Okuzawa, 62, to succeed Sunao Manabe, DVM, Ph.D. as Chief Executive Officer (CEO), effective April 1, 2025. Dr. Manabe will ...

“Thumbs Up” gives faculty and staff the chance to recognize others on campus for a job well done. We would like to hear about those people whose hard work and commitment contribute to the success of ...

The Japanese pharma had one asset rejected by the FDA and withdrew a regulatory application for another, but already this ...

(RTTNews) - Japanese healthcare firm Daiichi Sankyo Co., Ltd (DSKYF.PK) announced Friday the appointment of Hiroyuki Okuzawa as Chief Executive Officer, succeeding Sunao Manabe, with effect from ...